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Abstract 
Background: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease affecting the axial skeleton 
and peripheral joints. The etiology of this disease remains poorly understood, but interactions between genetic and 
environmental factors have been implicated. The present study identified differentially expressed proteins in the syno‑
vial fluid (SF) of AS patients to elucidate the underlying cause of AS.
Methods: A cohort of 40 SF samples from 10 AS and 10 each of rheumatoid arthritis (RA), gout, and osteoarthritis 
(OA) patients were analyzed by liquid chromatography tandem mass spectrometry (LC–MS/MS) to identify differen‑
tially expressed proteins specific to AS. The label‑free LC–MS/MS results were verified by western blotting.
Results: We identified 8 proteins that were > 1.5‑fold upregulated in the SF of AS patients compared to that of 
the disease control groups, including HP, MMP1, MMP3, serum amyloid P‑component (APCS), complement factor 
H‑related protein 5 (CFHR5), mannose‑binding lectin 2 (MBL2), complement component C9 (C9), and complement 
C4‑A (C4A). CFHR5 and C9 were previously found in serum from AS patients, while APCS was previously found in SF 
as well as in serum. However, the present study has identified C4A, and MBL2 as potential AS biomarkers for the first 
time. The expression levels of MMP3, C9, and CFHR5 were verified in AS SF using western blotting.
Conclusion: We performed quantitative comparative proteomic analysis using by LC–MS/MS of the SF from four 
disease states: RA, gout, and OA. This systematic comparison revealed novel differentially expressed proteins in AS SF, 
as well as two previously reported candidate biomarkers. We further verified the expression of MMP3, C9 and CFHR5 
by western blot. These proteins may serve as diagnostic or prognostic biomarkers in patients with AS, and may thus 
improve the clinical outcomes of this serious disease.
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Background
Ankylosing spondylitis (AS) is a chronic inflamma-
tory rheumatic disease, affecting the axial skeleton and 
peripheral joints, that occurs in 0.5% of the general popu-
lation [1]. Without proper clinical treatment, AS causes 
permanent structural changes, leading to progressive 
disability that affects the quality of life [2]. While the 
exact etiology of this disease remains poorly understood, 
it may be caused by interactions between genetic and 
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environmental factors [3]. AS represents an increasing 
financial burden on both patients and the healthcare sys-
tem [4, 5].
AS is defined by the presence of definite structural 
changes in the sacroiliac joints. Although several pos-
sibilities for the etiology of AS, including human leuko-
cyte antigen (HLA)-B27 and tumor necrosis factor-alpha 
(TNF-α), have been proposed as a therapeutic target [2, 
4, 5], no clear cause for AS has been identified. Periph-
eral arthritis is an important feature of spondyloarthritis 
(SpA) in general [5, 6]. Swelling of the knees with inflam-
matory pain is a representative symptom of peripheral 
arthritis, and work-up for peripheral arthritis can identify 
all forms of SpA early and differentiate it from other arth-
ritides. The synovial fluid (SF) from the knees may there-
fore contain diagnostic biomarkers for AS disease.
SF lubricates the joints, and consists of hyaluronic 
acid, inflammatory cells, and secreted proteins from the 
synovial fibroblasts, synovial membranes, and inflamma-
tory cells [7]. Normally, SF is present in small amounts 
in all joints, acting as joint lubricant and providing nutri-
tion for articular cartilage. However, when inflammation 
occurs, synovial cells secrete a large amount of synovial 
fluid and become the subjects of an inflammatory reac-
tion that destroys the joints. Arthrocentesis is the extrac-
tion of synovial fluid and has been used for differential 
diagnosis in patients with inflammatory arthritis [8]. 
Although serologic and imaging techniques have been 
developed to diagnose rheumatic diseases, synovial 
fluid analysis is still used as an important diagnostic tool 
for differential diagnosis of arthritis, especially acute 
arthritic disease, since SF is in contact with the primary 
tissues affected by arthritic diseases and is implicated 
in the disease pathophysiology. Therefore, it is an excel-
lent biofluid for the discovery of candidate biomarkers in 
arthritis-related diseases like AS [9].
In the last decade, many proteomic studies in the area 
of rheumatic diseases have been published [10–14], 
largely with the aim of diagnosing disease and evaluat-
ing disease activity/severity and therapeutic response 
[11, 12]. Different rheumatic disease samples with 
complicated pathologic structure, such as blood, SF, 
synovial tissue, and urine, have been investigated for 
system-wide discovery and validation of rheumatoid 
arthritis biomarkers [15].  Currently used diagnostic 
tests for rheumatoid arthritis (RA) include rheumatoid 
factor and anti-CCP antibodies (anti-cyclic citrulli-
nated peptide antibodies, anti-CCP Ab) [16]. However, 
there is still no clinically available protein biomarker for 
early diagnosis and monitoring of AS. Although HLA-
B27 is currently used for AS diagnosis, it has a high 
incidence of false positives. Although there were differ-
ences by race, the frequency of HLA-B27 was 4% in the 
normal control group and 83.3% in the patients with 
ankylosing spondylitis. Patients with negative HLA-B27 
tend to be delayed in diagnosis because the symptoms 
are not typical. Therefore, the discovery of new robust 
biomarkers for AS is required for effective early diagno-
sis and treatment. In the present study, we performed 
a quantitative proteomics comparison of SF proteins 
isolated from AS patients [17] and three other arthritis 
patient groups (RA, gout, and OA). OA is a non-inflam-
matory arthritis, and was included as a disease control 
for inflammatory arthritic diseases [18], while both 
RA and gout were disease controls for inflammatory 
arthritis from different pathologic origins [19]. Follow-
ing immunodepletion of super-abundant proteins and 
label-free quantitative proteomics, we found eight AS-
specific and differentially expressed proteins in the AS 
group compared to the disease control groups. Further 
western blot verification confirmed the discriminatory 
ability of seven of these proteins in AS patients. Among 
these, MMP3 (Matrix metalloproteinase-3), C9 (com-
plement component C9) and CFHR5 (Complement fac-
tor H-related protein 5) are upregulated in the SF of AS 




Ten patients with AS were recruited from an outpatient 
rheumatology clinic in Hanyang University Hospital for 
Rheumatic Diseases, Seoul, South Korea. An additional 
30 patients treated at Keimyung University Dongsan 
Hospital, Daegu, South Korea were recruited as disease 
control groups (10 OA, 10 gout, and 10 RA). These 
patient SF samples (first cohort) were used for the LC–
MS/MS experiments and the associated western blot ver-
ification. We further recruited five more patient samples 
per each patient group (second cohort) for the independ-
ent western blot verification experiments (5 AS, 5 OA, 
5 gout, and 5 RA). The patients met the 1984 New York 
criteria for ankylosing spondylitis [17] and the Ameri-
can College of Rheumatology criteria for RA [16], knee 
OA [18], and acute gout [19]. We collected demographic 
and clinical data from the subjects, including age, gen-
der, disease duration, blood chemistry, and concomitant 
treatment. We provide the summary statistics (Table  1) 
and the original data including the diagnosis, clinical 
data, and current treatments of each patient enrolled 
in this study (Additional file  1: Table  S1). The samples 
were obtained after getting informed consent from the 
patients. The study was approved by the ethical commit-
tee of the Keimyung University Dongsan Hospital (IRB 
2015-12-022).
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Synovial fluid sample collection and processing
Synovial fluid was collected by arthrocentesis in patients 
with knee joint pain and swelling. Contaminated bloods 
during arthrocentesis and samples where synovial fluids 
were generated for reasons other than the respective dis-
eases were excluded. After centrifugation at 500×g for 
10 min, five 1 mL vials of supernatant and 1 vial of sedi-
ment from each sample were stored at − 80  °C through 
the Keimyung University Dongsan Hospital Human 
Resource Bank.
Immunodepletion of abundant proteins with MARS 
cartridge
We used a Multiple Affinity Removal System (MARS) 
Hu-14 spin cartridge (Agilent, 5188–6560), which con-
tains a bulk of immobilized antibodies against the 14 
most abundant proteins (albumin, IgG, antitrypsin, IgA, 
transferrin, haptoglobin, fibrinogen, alpha-2-macroglob-
ulin, alpha-1-acid glycoprotein, IgM, apolipoprotein A1, 
apolipoprotein A2, complement C3 and transthyretin), 
which are known to occupy about 95% of plasma pro-
teome [20], enabling immunodepletion of such abundant 
proteins in SF. The 0.22  μm membrane filter (Agilent) 
was used to remove particulates from the fluid samples 
by centrifugation at 100xg for 1.5 min. The flow-through 
was mixed with Buffer A LOAD/WASH (Agilent) and 
depleted according to the manufacturer’s instructions. 
During the depletion, flow-through was collected, and 
protein concentration was determined using a BCA 
assay.  The column was routinely regenerated by eluting 
bound high-abundance proteins with buffer B and neu-
tralizing with buffer A before further use. The acquired 
proteins were directly digested for total proteomic 
analysis.
Peptide sample preparation
In-solution tryptic digestion and peptide cleanup were 
simultaneously performed in a 96-well plate for high 
reproducibility. Each depleted sample was supplemented 
with 8 M urea in 100 mM ammonium bicarbonate (ABC) 
(Sigma) and incubated at room temperature for 20 min. 
The samples were homogenized by vortexing and soni-
cation twice. To each sample, dithiothreitol (Sigma) was 
added to be 10 mM for protein reduction at RT for 1 h. 
Then, iodoacetamide (Sigma) was added to be 30  mM 
for the cysteine alkylation at RT for 30 min in the dark. 
Samples were then diluted with 100  mM ABC prior 
to the addition of trypsin (MS grade, Pierce) at 1:50 of 
trypsin:sample ratio (w/w), and incubated at 37  °C for 
overnight. The trypsin was inactivated by acidification 
with 0.4% trifluoroacetic acid (Sigma). The acidified 
digests were immediately processed using a Sep-Pak C18 
96-well plate (100 mg C18 sorbent per well, Waters). The 
peptides were eluted with 80% acetonitrile and then dried 
in a vacuum centrifuge.
LC–MS/MS experiments
We performed a label-free quantitative proteomics using 
LC–MS/MS experiments in synovial fluid samples. Forty 
LC–MS/MS experiments were carried out on an Orbit-
rap Fusion Lumos mass spectrometer (Thermo Fisher 
Scientific) coupled to a nanoACQUITY UPLC (Waters) 
with an in-house-packed trap (150  μm i.d. × 3  cm) and 
analytical column (75 μm i.d. × 100 cm) using 3 μm Jupi-
ter C18 particles (Phenomenex). The LC gradient was as 
follows: from 5% to 40% solvent B (acetonitrile with 0.1% 
formic acid) for 130 min, then 40% to 80% solvent B for 
5  min, holding at 80% solvent B for 10  min, and then 
equilibrating at 95% solvent A (water with 0.1% formic 
acid) for 30  min. Full MS data were acquired in a scan 
range of 375–1575 Th at a resolution of 60,000 at m/z 
200, with an automated gain control (AGC) target value 
of 4.0 × 105 and a maximum ion injection time of 50 ms. 
The maximal ion injection time for MS/MS was 50  ms 
at a resolution of  15,000 and an AGC target value of 5 
×  104. The dynamic exclusion time was set to 30 s. The 
resulting forty MS raw files were analyzed using MaxLFQ 
in Maxquant software (Fig. 1).
Data analysis
MaxQuant (v.1.5.1.2) [21] was used to compare the 
acquired spectra to the UniProt human database 
Table 1 The clinical and  laboratory features of  patients with  ankylosing spondylitis, rheumatoid arthritis, gout, 
and osteoarthritis
CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; F: female; M: male
Parameters Ankylosing spondylitis Rheumatoid arthritis Gout Osteoarthritis
No. of patients 10 10 10 10
Age (years) 32.6 ± 10.6 59.6 ± 11.6 62.8 ± 12.8 64.8 ± 8.5
Sex (M/F) 9/1 0/10 10/0 1/9
ESR (mm/h) 59.5 ± 39.7 32.7 ± 17.0 69 ± 21.3 (n = 5) 27.5 ± 15.2 (n = 4)
CRP (mg/dL) 4.9 ± 4.3 0.5 ± 3.7 3.4 ± 3.7 (n = 6) 0.1 ± 0.04 (n = 4)
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(obtained in June 2018). Carbamidomethylation of 
cysteine was selected as a fixed modification, while 
N-terminal acetylation and methionine oxidation 
were set as variable modifications. 1% of false discov-
ery rate (FDR) cutoff was applied at the levels of pep-
tide-spectrum match and protein. An initial precursor 
mass deviation of up to 4.5  ppm and a fragment mass 
deviation of up to 20 ppm were allowed. To maximize 
the protein identification in initial discovery stage, the 
criterion with minimum stringency, at least one unique 
peptide, was applied for the protein identification. Pro-
teins were quantified using the label-free quantifica-
tion (LFQ) algorithm in MaxQuant [22]. The option of 
‘match between runs’ was used for nonlinear retention 
time alignment. The match time window was 0.7  min, 
and the alignment time window was 20  min. Further 
statistical and bioinformatics analysis was performed 
using Perseus software (v.1.5.3.2) [23]. Proteins hit to 
the decoy database and contaminants, or proteins only 
identified by the peptide with modification sites such as 
methionine oxidation were filtered out prior to further 
analysis. A minimum of three valid protein quantifica-
tion values across each clinical group was required for 
protein quantification. The LFQ intensity of individual 
proteins in the AS group was compared with that of 
such proteins in the other clinical groups following log2 
transformation, i.e., AS vs OA, AS vs gout, and AS vs 
RA. Statistical analysis of the log2-transformed data 
was performed using two samples t-test (p value < 0.05). 
Proteins with fold change ≥ 1.5 or ≤ 0.67 between AS 
and other patient groups were considered to be differ-
entially expressed proteins (DEPs) for AS group. The 
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Fig. 1 a Schematic diagram of proteomics experimental workflow. Synovial fluids of ankylosing spondylitis (AS), osteoarthritis (OA), gout, and 
rheumatoid arthritis (RA) were subject to immunodepletion using the multiple affinity removal system (MARS) and followed by trypsinization and 
LC–MS/MS analysis. MaxQuant LFQ (MaxLFQ) analysis was carried out for quantitative comparison. b Venn diagram showing the unique and shared 
protein groups and peptides identified in the synovial fluid of each group
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Enrichment and network analysis
To explore functional enrichment in the identified pro-
teins in each of the clinical groups, GO analysis was per-
formed using DAVID (version 6.8) [24]. We identified 
biological processes and KEGG pathways [25] that were 
enriched in our DEP list with p values of less than 0.05. 
To construct a network representing the enriched GO 
terms, we selected DEPs that are involved in the enriched 
cellular processes. We then built a protein network 
model using protein interaction information obtained 
from STRING version 11 database [26]. The interaction 
network models were visualized using Cytoscape [27].
Western blot verification
We carried out western blot based verification experi-
ments for the candidates as AS-specific proteins from 
LC–MS/MS proteomic data. To reduce the viscosity of 
SF, samples were treated with hyaluronidase (Sigma, 
H3884) at room temperature for 5 or 10  min, and then 
diluted 1:10 in RIPA buffer (Thermo Fisher) containing 
both protease and phosphatase inhibitor (Roche Diag-
nostics GmbH). The diluted sample was incubated on 
ice for five min, then transferred into new tube and cen-
trifuged at 10,000×g at 4  °C for 15 min. Equal amounts 
of protein (30 μg) in each sample were aliquoted follow-
ing protein quantitation by BCA assay (Thermo Fisher). 
Samples were mixed with sodium dodecyl sulfate (SDS) 
loading buffer and separated using SDS polyacrylamide 
gel electrophoresis (Western Blotting Kit, Hoefer Inc.). 
Proteins were then transferred onto nitrocellulose mem-
branes (Amersham), blocked with 5% non-fat dried milk 
in tris-buffered saline containing 0.05% Tween-20 and 
immunoblotted with the appropriate primary and sec-
ondary antibodies. The antibodies used were as follows: 
rabbit polyclonal antibodies for C9 (1:5000, PA5-29093, 
Thermo Fisher), CFHR5 (1:500, ab175254, Abcam), 
MMP3 (1:5000, ab52915, Abcam), mannose-binding pro-
tein C (MBL2) (1:5000, ab189856, Abcam), complement 
C4-A (C4A) (1:5000, ab66790, Abcam), serum amyloid 
P-component (APCS) (1:5000, ab45151, Abcam), matrix 
metalloproteinase-1 (MMP1) (1:3000, ab38929, Abcam), 
anti-transferrin (1:5000, ab109503, Abcam), and per-
oxidase-conjugated AffiniPure Donkey anti-rabbit IgG 
(H + L) (1:10,000, Jackson Immunoresearch). Anti-trans-
ferrin (77 kDa) was used as a loading control [28].
Results
General characteristics of study subjects
The summary statistics and general characteristics of 
the study subjects are presented in Table  1 and Addi-
tional file 1: Table S1, respectively. The AS group was 32.6 
(± 10.6) years of age, with 7.0 (± 4.6) years mean disease 
duration, 80% HLA-B27 positive rate, 20% biologics utili-
zation, 59.5 (± 39.7) mm/h averaged ESR, and 4.9 (± 4.3) 
mg/dL averaged CRP. The RA group were all females at 
59.6 (± 11.6) years of age, with 4.9 (± 4.9) years mean dis-
ease duration, 90% rheumatoid factor and anti-CCP anti-
body positive rate, 30% biologics utilization, 32.7 (± 17.0) 
mm/h averaged ESR, and 0.5 (± 3.7) mg/dL averaged 
CRP. The gout group were all males at 62.8 (± 12.8) years 
of age, with 0.3 (± 0.9) years of disease duration, and 7.1 
(± 2.6) mg/dL concentration of serum uric acid. The OA 
group were 64.8 (± 8.5) years of age, with 5.5 (± 5.9) years 
mean disease duration.
Proteomic analysis of SF from AS, RA, gout, and OA patient 
groups
To obtain insight into the molecular basis of AS in the 
SF, we performed a LFQ intensity-based proteomic com-
parison of SF from AS patients and SF from patients with 
OA, gout, and RA (Fig. 1a). All SFs were first subjected 
to immunodepletion of the 14 most abundant proteins 
using an MARS kit, and then followed by LC–MS/MS 
experiments, resulting in the identification of 569 pro-
teins and 6103 peptides in the AS group, 874 proteins 
and 9991 peptides in the RA group, 456 proteins and 
5313 peptides in the OA group, and 873 proteins and 
8231 peptides in the gout group at < 1% FDR (Fig. 1b). A 
further MaxQuant analysis using ‘match between runs’ 
to minimize missing quantities between replicates and 
groups [21, 29] was then carried out. To resolve the AS-
specific DEPs against other disease groups, we performed 
a series of pairwise statistical comparisons of AS group 
versus three different control groups (OA, gout and RA) 
based on the LFQ intensity of commonly identified pro-
teins from ≥ 3 patients in each group using the Perseus 
software, resulting in 385, 500, and 485 quantifiable pro-
teins for AS vs OA, AS vs gout, and AS vs RA compari-
son sets, respectively (Additional file 2: Table S2). DEPs 
in such three comparison sets were defined as the pro-
teins with > 1.5 fold-change and < 0.05 p value and the 
corresponding numbers of up- and down-regulated DEPs 
were 102 and 84 for AS/OA set, 41 and 179 for AS/gout 
set, and 69 and 151 for AS/RA set, respectively (Addi-
tional file 3: Table S3). Intriguingly, we found that eight of 
the DEPs were AS-specifically up-regulated (HP, MMP1, 
MMP3, APCS, CFHR5, C9, C4A, and MBL2 in Table 2), 
whereas a total of 24 proteins including immune-related 
proteins such as PLA2G2A (Phospholipase A2) were 
commonly downregulated in AS samples against three 
other arthritides (Fig. 2a).
Gene ontology analysis to clarify the molecular basis for AS
Next, we tried to gain insight into the functional roles of 
the DEPs associated with AS (Fig. 2a and Table 2) via GO 
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analysis of the up- and downregulated DEPs (Additional 
file 4: Table S4). Interestingly, the AS-specifically upregu-
lated proteins showed enriched patterns largely to the 
immune response-related biological processes (Fig.  2b). 
In detail, the AS-specifically upregulated proteins vs 
OA or gout were strongly associated with the innate 
immune response (Fig. 2b). The enriched GO terms sug-
gested that the AS-specifically upregulated proteins may 
play an important role in the complement activation and 
the inflammatory response. In addition, the GO terms 
involved in metabolic processes, protein oligomerization, 
proteolysis, and extracellular matrix disassembly were 
also enriched in the AS-specific DEPs. On the contrary, 
the GO terms related to various biological processes 
including extracellular matrix organization, collagen 
fibril organization, and cellular structure were enriched 
in the AS-specifically downregulated DEPs (Fig. 2c).
Protein–protein interaction network describing AS
To better understand the cellular networks that are 
altered in the synovial fluid of AS patients, we created 
protein–protein interaction network models of AS-
specific upregulated DEPs using the STRING database 
(Fig.  3). Four important processes were enriched in the 
AS-specific upregulated DEPs: innate immune response, 
complement activation, platelet degranulation, and gly-
colytic process. We found that APCS (innate immune 
response), C9, C4A, CFHR5, and MBL2 (complement 
activation), which are common in AS SF, are known to 
interact based on this network.
Verification by western blot analysis
Following the LC–MS/MS analysis, the levels of 7 DEPs 
in SF (MMP3 (50  kDa), CFHR5 (70  kDa), C9 (60  kDa), 
MBL2 (26  kDa), C4A (95  kDa), APCS (25  kDa), and 
MMP1 (50  kDa), except for HP, which occupies a large 
portion in synovial fluid) were verified by western 
blot using specific primary antibodies. Figure  4 clearly 
showed that the three candidates (MMP3, CFHR5, and 
C9) are reproducibly represented as AS-specific proteins 
in both original (Fig.  4a) and additional independent 
(Fig.  4b) sample sets, further verifying the results from 
mass spectrometry. MMP3 was considered as a positive 
control because it has been known to be highly expressed 
in the SF of AS patients [30], expectedly showing the sig-
nificantly increased expression levels in AS SF compared 
to those in the other clinical groups. MMP1 protein was 
excluded due to the vain western blot detection and 
transferrin protein was included in western blot experi-
ments as a control of loading amount.
However, the AS-specifically upregulated expressions 
of the remaining three proteins (C4A, MBL2 and APCS) 
in mass spectrometry were not clearly verified by the 
original western blot experiments (Additional file 5: Fig-
ure 1a). Intriguingly, C4A protein showed a clear AS-spe-
cific pattern in the independent sample set (Additional 
file 5: Figure 1b), suggesting that the C4A protein needs 
to be further verified or included to the validation candi-
dates of AS-specific markers.
Discussion
Early diagnosis of AS is difficult because the etiology is 
not clear and there is no specific diagnostic indicator 
[31]. Mass spectrometry-based proteomics is a state-of-
the-art analytical technique that enables the discovery 
of indicator proteins for the diagnosis and treatment of 
diseases. There has been a recent expansion in proteom-
ics research on a number of different rheumatic diseases 
[32].
In the present study, we performed comprehensive 
proteomic profiling and western blot analysis of SF 
obtained from patients with AS and SF obtained from 
patients with comparative diseases (RA, gout, and OA). 
SF samples obtained from patients with AS and the three 
Table 2 List of  proteins with  increased levels in  the  synovial fluid of  ankylosing spondylitis patient group vs other 
disease groups
AS: ankylosing spondylitis; OA: osteoarthritis; RA: rheumatoid arthritis






HP Haptoglobin 2.67 5.93 27.97
MMP3 Matrix metalloproteinase‑3 2.02 2.63 10.13
CFHR5 Complement factor H‑related protein 5 1.61 4.52 3.23
C9 Complement component C9 1.85 1.75 1.82
MBL2 Mannose‑binding protein C 1.68 1.52 1.61
C4A Complement C4‑A 1.92 2.02 1.63
APCS Serum amyloid P‑component 15.69 4.81 6.53
MMP1 Matrix metalloproteinase‑1 1.97 2.75 14.96
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disease control groups were quantified using highly sen-
sitive LC–MS/MS and LFQ-based analysis. We discov-
ered eight biomarker candidate proteins (HP, MMP3, 
CFHR5, C9, MBL2, C4A, APCS, and MMP1) with > 1.5 of 
fold change in AS compared to that in the other groups. 
Western blot experiments for seven proteins (with the 
exception of HP) were performed to further verify the 
differential expression level. As a result, three proteins 
(MMP3, CFHR5 and C9) were solidly verified to be 
highly expressed in the SF of patients with AS.
MMP family proteins are involved in the pathogen-
esis of arthritis. In particular, MMP3 is a protease that 
is synthesized and secreted by fibroblasts and chondro-
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Fig. 2 a Reverse cumulative plots of protein fold change in the synovial fluid from each disease group. The most commonly upregulated 8 
proteins (HP, MMP1, MMP3, APCS, CFHR5, C9, C4A, and MBL2) are highlighted. b, c Gene ontology (GO) analysis of differentially expressed proteins 
in the synovial fluid of the AS group compared to in the OA, gout, and RA groups. Heatmaps showing significantly enriched GO biological process 
terms (p < 0.05) for differentially expressed proteins. The red color in the heatmap indicates a significant upregulation (b) and blue color indicates 
downregulation of the biological process (c)
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such as MMP1, MMP7, and MMP9 [33]. A recent meta-
analysis suggests that the serum levels of MMP3 rise in 
AS patients [29]. The validity of our results was further 
enhanced by the discovery of previously researched AS 
relevant protein, MMP3.
CFHR5 plays an important role in the alternative path-
way complement system, and binds to C3 to activate it 
[34]. This protein is highly expressed in the serum of AS 
patients [35]. In addition, high concentrations of CFHR5 
were observed in the plasma of patients with systemic 
lupus erythematosus, an autoimmune disease [36]. C9 is 
a member of the membrane attack complex (MAC) com-
plement system, and causes lysis by inducing pores in the 
cell membrane after activating C5, the final stage of the 
complement system [37]. The levels of this protein are 
elevated in the serum of AS patients [35].
Unlike the proteomic result, MBL2 showed inconsist-
ently and slightly upregulated expression level accord-
ing to the western blotting results. The expression of 
MBL2 was observed in 11 out of 15 cases of AS in the 
western blot, compared to six in RA, six in gout, and 
three in degenerative arthritis. MBL2 has an ability to 
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Fig. 3 Network modelling of differentially expressed proteins in the synovial fluid of the AS group versus the a OA, b gout and c RA group. Protein–
protein interaction network showing the biological processes affected, including the immune response, platelet degranulation, cell–cell adhesion 
etc. The colors of the nodes represent proteins with increased (red) or decreased (green) levels in the synovial fluid of the AS group compared to in 
the other groups. The connection between nodes (solid grey lines) shows either a regulatory role or physical interaction between proteins
Page 9 of 11Lee et al. Clin Proteom           (2020) 17:20  
recognize carbohydrate types found on pathogenic 
microbial surfaces. MBL2 initiates the lectin pathway 
and opsonizes apoptotic and necrotic cells [38].
C4A, a complementary protein with MBL2, showed 
vague expression pattern in the original western blot 
set, while a clear AS-specific pattern in the independ-
ent western blot set. C4A is involved in the classi-
cal pathway of the complement system. Deficiency of 
C4A is associated with systemic lupus erythematosus 
and type 1 diabetes mellitus, and its overexpression is 
associated with mental disorders such as schizophrenia 
and bipolar disorder [39]. The complement system is an 
important mechanism of humoral and innate immu-
nity. Suppressing the complement system in an animal 
model of AS may improve AS treatment [40]. The com-
plement system is active in patients with systemic scle-
rosis, a musculoskeletal disorder [41].
APCS is associated with the innate immune sys-
tem and is known to have increased expression in the 
SF and serum of AS patients [35, 42]. However, APCS 
showed quite consistent expression patterns for all SF 
samples in western blot data, even though MS-based 
proteomics revealed significantly higher fold-changes 
of APCS protein in the AS group than the other groups 
(AS/RA: 15.69, AS/gout: 4.81, AS/OA: 6.53) (Table  2). 
Previously, CRP and APCS were shown to have 51% 
sequence homology in rats [43]. In this regard, the anti-
body used in this study might not be exclusively specific 
to APCS, simultaneously detecting other inflamma-
tory markers too. The antibody-based verification 
approach may therefore not be suitable in all cases, and 
an alternative approach may be better for this particu-
lar protein. For instance, targeted proteomics such as 
multiple reaction monitoring can be an alternative. The 
last candidate, MMP1, a protein mainly expressed in 
bone metabolism, was not detected by western blot in 
all disease groups, and should be verified further with 
other approach.
The limitations of the present study are the following: 
the relatively small number of patients included due 
to the difficulty in obtaining clinical sample donor and 
the lack of further validation method beyond western 
blotting. Further validation will increase the likelihood 
of identifying biomarkers for AS, as will increasing the 
number of samples and using alternative sample types 
including urine, serum, synovial membrane, and animal 
models.
Conclusions
In total, 1089 proteins were identified by label-free 
comparative proteomic analysis in the SF of patients 
with AS, RA, gout, and OA. This is the largest dataset 
of proteins identified in the synovial fluid to date. This 
is also the first time that three diseases (RA, gout, and 
OA) have been used simultaneously as disease control 
groups during proteomic profiling of AS. Out of the sig-
nificantly dysregulated proteins, eight were significantly 
increased in the SF of AS patients compared to that of 
patients of the other three diseases. Out of these, MBL2 
and C4A were the first proteins previously reported as 
AS markers, while the remaining six proteins were first 
reported as AS markers in SF sample in this study. Four 
out of the eight proteins are part of the complement 
system, which appears to be highly associated with 
AS. Altogether, these results suggest an important role 
for complement signaling during AS disease progres-
sion, and this avenue of enquiry may provide insight 
into the underlying molecular mechanisms of AS. The 
clinical utility of the putative biomarkers identified in 
the present study should be further validated in a larger 
cohort.










Fig. 4 Verification of C9, CFHR5, and MMP3 in synovial fluid by western blot. a Western blot analysis in the original synovial fluid sample set: A; 
AS (n = 10), R; RA (n = 10), G; gout (n = 10), and O; OA (n = 10). b Western blot analysis in the independent sample set: AS (n = 5), RA (n = 5), gout 
(n = 5), OA(n = 5). Transferrin was used as an input amount control
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